S2419 BioFront Kickoff:

Adding a Biotherapeutic to Immunotherapy for Advanced Renal Cell Carcinoma

FRIDAY, OCT 9 • 4:15 – 5:15 PM CT • COMISKEY (CONCOURSE LEVEL, WEST TOWER) & ONLINE

S2419: Phase III Double-Blinded Trial of Immune-Based Therapy with a Live Biotherapeutic MO-03 or Placebo for Frontline Therapy of Advanced Clear Cell Renal Cell Carcinoma (BioFront Trial)

S2419 asks if modulating the gut microbiome can enhance immune checkpoint inhibitor efficacy in patients with advanced clear cell renal cell carcinoma.

S2419 was designed to be easy to open and enroll to, across all types of treatment sites. Its intervention is a once-daily capsule requiring no refrigeration or special handling.

The kickoff will provide information on the trial's

scientific rationale and study design • key eligibility and treatment details • correlative science components • biospecimen collection • safety monitoring • quality-of-life objectives • accrual strategies


S2419 activated in April 2026. Its enrollment goal is 718 patients.

Attend the S2419 BioFront Kickoff. Bring your questions for the study team.

All NCTN and NCORP investigators and research staff are invited.

Hybrid session: Attend IN-PERSON or ONLINE

PRESENTERS



Pedro C. Barata, MD, MSc
Study Chair




Ulka Vaishampayan, MD
Study Co-Chair



Monty Pal, MD
Study Co-Chair



Laura Esfeller, MA
GU Renal Subcommittee Patient Advocate



Nazli Dizman, MD
TM Co-Chair